Pimecrolimus 1% cream for the treatment of rosacea
Article first published online: 28 SEP 2011
© 2011 Japanese Dermatological Association
The Journal of Dermatology
Volume 38, Issue 12, pages 1135–1139, December 2011
How to Cite
KIM, M.-B., KIM, G.-W., PARK, H.-J., KIM, H.-S., CHIN, H.-W., KIM, S.-H., KIM, B.-S. and KO, H.-C. (2011), Pimecrolimus 1% cream for the treatment of rosacea. The Journal of Dermatology, 38: 1135–1139. doi: 10.1111/j.1346-8138.2011.01223.x
- Issue published online: 22 NOV 2011
- Article first published online: 28 SEP 2011
- Received 6 September 2010; accepted 14 December 2010.
- calcineurin inhibitor;
Rosacea is a common inflammatory skin disorder; the pathogenesis is unclear. Various treatment options for rosacea are available, but most have limited effectiveness. The aim of this study was to investigate the efficacy and safety of 1% pimecrolimus cream for the treatment of rosacea. Thirty patients with rosacea were enrolled in this 4-week, single-center, open-label study of 1% pimecrolimus cream. Patients were instructed to apply the cream to their faces twice daily and were not permitted to use any other agents. Clinical efficacy was evaluated by a rosacea grading system using photographic documentation and a mexameter. The 26 patients who completed the study experienced significantly reduced rosacea clinical scores from 9.65 ± 1.79 at baseline to 7.27 ± 2.11 at the end of treatment (P < 0.05). The mexameter-measured erythema index decreased significantly from 418.54 ± 89.56 at baseline to 382.23 ± 80.04 at week 4 (P < 0.05). The side-effects were mostly transient local irritations. The results of this study suggest that 1% pimecrolimus cream is an effective and well-tolerated treatment for patients with mild to moderate inflammatory rosacea.